Edward Chow

Is #personalization of drug combinations possible/ feasible in cancer care? Check out our latest publication in @ScienceTM: science.org/doi/10.1126/sc…. Fantastic collaboration with @echow310 and clinical/ scientific colleagues @NUSMedicine @SingHealthSG @csi_singapore 1/n

Great work led by @ChesterLeeDrum

Really chuffed to have our work accepted as an oral presentation at #ASH2021 ash.confex.com/ash/2021/webpr… We report our clinical experience with #personalized combination treatments in relapsed #lymphoma - a fantastic collaboration with @echow310 and colleagues across Singapore.

Hilarious. Cambridge flashbacks @rsyf2?

Super proud of our first publication of 2021! MYC synthetic lethality and how AI can improve synthetic lethal drug combination design.#Cancer #medicine #AI cell.com/trends/pharmac…

DEADLINE EXTENDED! The closing date for abstract submission has been extended to 11 January 2021. Submit your abstracts today: csi.nus.edu.sg/web/epigenetic…

Our bond free premium scholarship provides you with the opportunity to work with a dynamic team of renowned scientists in an intellectually stimulating environment. Apply for the CSI PhD Graduate Program now! csi.nus.edu.sg/web/graduate-p…

Do not miss the opportunity to present your research at the Epigenetics in Cancer Symposium 2021! Abstract submission closes on 28 December. Submit your abstract today! csi.nus.edu.sg/web/epigenetic…

It was a privilege working with an amazing team on this paper @TrendsinBiotech! @WeAreWisDM @TheN1Institute @BME_NUS @chngwj @PersonalizedMed @The__Liver @echow310

Abstract submission is now OPEN for the Epigenetics in Cancer Symposium 2021! Find out more here: rb.gy/hkutsw Register today at: rb.gy/9bhdij

The Epigenetics in Cancer Symposium (15-17 Feb 2021) is a high profile conference with a lineup of internationally distinguished speakers. Registration is now open: cutt.ly/2hqOAIR More info available here: cutt.ly/LhqOPl3 @denniskappei @DefossezPierre

ICYMI: The NADIM study: #Neoadjuvant #chemotherapy and #nivolumab in resectable non-small-cell #lungcancer: an open-label, multicentre, single-arm, phase 2 trial #NSCLC #lcsm thelancet.com/journals/lanon…

Check out our recent paper in Adv. Mat. on non-genetic modifications of cells by depositing nano-complexes of biomomecules on cell surfaces. Anti-PDL1 nano-complexes on macrophages markedly improved tumor response in mice doi.org/10.1002/adma.2… @wyssinstitute @hseas

Free registration is open for the virtual @CSI_Singapore Frontiers in Cancer Science Annual Conference, Nov 2-6. We are partnering with FCS to organize three AACR-FCS Education Sessions for graduate students and early-career investigators. Learn more: nus.edu/2HJMeBq

Good things happen when engineering principles are applied to cancer research and drug development. Enjoyed this review by @khademh about AI/Engineering applied towards IO. #ArtificialIntelligence #oncology #Immunotherapy onlinelibrary.wiley.com/doi/full/10.10…

A recent review in our SLAS Technology comprehensively covers how AI is applied at every step of drug development, from target identification to patient stratification. #ArtificialIntelligence #Pharmaceutical #PrecisionMedicine #SLAS journals.sagepub.com/doi/abs/10.117…